Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06899802 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 400 to confirmed 411
    • Site details revised at 9 of 9 sites
    v5
  2. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 9 of 9 sites
    v4
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 9 of 9 sites
    v3
  4. Site details revised at 8 of 9 sitesv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of disease induced by VEEV and EEEV, in persons aged 18 years and older at high risk of exposure.
Trial Details
NCT Number NCT06899802
Lead Sponsor Bavarian Nordic
Collaborators: JPM CBRN Medical
Conditions
(from sponsor)		 Encephalitis
Related terms Encephalitis, Encephalomyelitis, Equine
Enrollment 411 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov